EXFO
EXFO Inc. (NASDAQ: EXFO, TSX: EXF), the communications industry’s test, monitoring and analytics experts, and Openreach , the United Kingdom’s largest digital infrastructure firm, today announced their collaboration on a major initiative to accelerate Full Fibre deployment, and enhance the quality of build and experience for customers across the UK.
The project is essential for delivering next-generation Fibre-to-the-Premises (FTTP) networks, which provide the digital infrastructure required to work, learn and socialize. As part of its industry-leading Fibre First programme , Openreach has committed to delivering 20 million homes passed with FTTP by the mid-to late 2020s, assuming it has the right investment conditions. Openreach has also committed to building out this new digital infrastructure to 4.5 million premises by the end of March 2021.
Following a competitive tender process, Openreach has awarded EXFO a contract to supply optical test heads and test access switching for this initiative. With its cloud-based Nova Fiber solution , EXFO will equip Openreach to assure its build, thereby accelerating the programme and avoiding costly return visits to fix connection problems—additional “truck rolls” more than double operators testing costs.1 Following installation, Openreach will be able to remotely monitor its fibre infrastructure supporting the in-life operations of its Full Fibre service.
This announcement comes as Openreach hit a record build rate for its Full Fibre broadband programme. Openreach engineers are now delivering faster, more reliable connectivity to another 40,000 homes and businesses every week, or the equivalent of a home every 15 seconds.
Peter Bell, Director, Network Technology, Openreach: “We know that now more than ever that being connected matters. We’re convinced that our new Full Fibre network can play a crucial role in keeping the nation connected. This year, our build has been gathering pace and momentum, and we’re determined to match that rapid speed of deployment with the highest standards of build quality build and customer service.
EXFO will help us get there. As a long-term Openreach partner, EXFO was selected thanks to its proven ability to provide fast, automated qualification of fibre builds, and for its unique iOLM OTDR technology. We’re committed to working with the best-in-class to maintain our position as the UK’s leading Full Fibre builder and we’re excited to lead the way as we continue to deliver high-quality network connections to homes and businesses across the UK.”
Wim te Niet, Vice President, Sales – EMEA, EXFO: “Openreach is an early mover in adopting permanent fibre monitoring technology, which will eventually cover all households in the UK. Currently, the FTTH/B penetration rate in the UK stands at 18%2 , and Openreach has an ambitious plan to build out Full Fibre to millions of households and businesses. We see a similar wave in other key European markets like Germany. I believe network operators across Europe will soon follow Openreach’s lead to ensure first-time-right installations, reduce turn-up failures, and substantially reduce truck rolls for service calls. As for markets with high FTTH/B penetration rates, telecom operators are finding they need sophisticated automated monitoring tools to ensure superior customer experience. EXFO’s innovative Nova Fiber solution gives them these abilities.”
About EXFO
EXFO
(NASDAQ: EXFO) (TSX: EXF) develops smarter test, monitoring and analytics solutions for fixed and mobile network operators, webscale companies and equipment manufacturers in the global communications industry. Our customers count on us to deliver superior network performance, service reliability and subscriber insights. They count on our unique blend of equipment, software and services to accelerate digital transformations related to fibre, 4G/LTE and 5G deployments. They count on our expertise with automation, real-time troubleshooting and big data analytics, which are critical to their business performance. We’ve spent over 35 years earning this trust, and today 1,900 EXFO employees in over 25 countries work side by side with our customers in the lab, field, data center and beyond.
About Openreach
Openreach Limited is the UK’s digital network business. We’re 35,000 people, working in every community to connect homes, schools, shops, banks, hospitals, libraries, mobile phone masts, broadcasters, governments and businesses – large and small – to the world. Our mission is to build the best possible network, with the highest quality service, making sure that everyone in the UK can be connected. We work on behalf of more than 660 communications providers like SKY, TalkTalk, Vodafone, BT and Zen, and our broadband network is the biggest in the UK, passing more than 31.8m UK premises. Over the last decade we’ve invested more than £14 billion into our network and, at more than 185 million kilometres, it’s now long enough to wrap around the world 4,617 times. Today we’re building an even faster, more reliable and future-proof broadband network which will be the UK’s digital platform for decades to come. We’re making progress towards our FTTP target to reach 20m premises by mid-to late 2020s. We’ve also hired more than 3,000 trainee engineers this past financial year to help us build that network and deliver better service across the country. Openreach is a highly regulated, wholly owned, and independently governed unit of the BT Group. More than 90 per cent of our revenues come from services that are regulated by Ofcom and any company can access our products under equivalent prices, terms and conditions. For the year ended 31 March 2020, we reported revenue of £5bn.
For more information, visit www.openreach.co.uk/
.
Email: press@openreach.co.uk
Forward-Looking Statements - EXFO
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and we intend that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements are statements other than historical information or statements of current condition. Words such as may, expect, believe, plan, anticipate, intend, could, estimate, continue, or similar expressions or the negative of such expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events and circumstances are considered forward-looking statements. They are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in forward-looking statements due to various factors including, but not limited to, macroeconomic uncertainty, including trade wars and recessions; our ability to successfully integrate businesses that we acquire; capital spending and network deployment levels in the communications industry (including our ability to quickly adapt cost structures to anticipated levels of business and our ability to manage inventory levels with market demand); future economic, competitive, financial and market conditions; consolidation in the global communications test, monitoring and analytics solutions markets and increased competition among vendors; capacity to adapt our future product offering to future technological changes; limited visibility with regard to the timing and nature of customer orders; delay in revenue recognition due to longer sales cycles for complex systems involving customers’ acceptance; fluctuating exchange rates; concentration of sales; timely release and market acceptance of our new products and other upcoming products; our ability to successfully expand international operations and to conduct business internationally; and the retention of key technical and management personnel. Assumptions relating to the foregoing involve judgments and risks, all of which are difficult or impossible to predict and many of which are beyond our control. Other risk factors that may affect our future performance and operations are detailed in our Annual Report, on Form 20-F, and our other filings with the U.S. Securities and Exchange Commission and the Canadian securities commissions. We believe that the expectations reflected in the forward-looking statements are reasonable based on information currently available to us, but we cannot assure you that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this document. Unless required by law or applicable regulations, we undertake no obligation to revise or update any of them to reflect events or circumstances that occur after the date of this document.
1
Omnia operator survey: test and measurement efficiency (2020)
2
Data taken from recent Ofcom Connected Nations report 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
